{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062031","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.534962+00:00","generated_at":"2026-06-08T06:41:15.616418+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Trevi Therapeutics Q3 2023 net loss $7.7M; initiates Phase 2a RIVER trial for Haduvio in RCC","bullets":["Net loss $7.7M in Q3 2023 vs $8.3M in Q3 2022; cash, equivalents $88.9M.","Initiated Phase 2a RIVER trial of Haduvio in refractory chronic cough; topline data expected H2 2024.","Plan to initiate Phase 2b dose-ranging trial for chronic cough in IPF in Q4 2023; Phase 1b trial in Q1 2024.","Open-label extension of PRISM trial in prurigo nodularis showed sustained itch reduction and safety over 52 weeks.","R&D expenses $6.3M, G&A $2.7M; other income $1.3M due to higher interest income."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062031","json":"https://secwatch.observer/filing/0000950170-23-062031.json","markdown":"https://secwatch.observer/filing/0000950170-23-062031.md","text":"https://secwatch.observer/filing/0000950170-23-062031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000095017023062031/0000950170-23-062031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000095017023062031/trvi-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:41:15.616418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ff17bb7560df8076eda5f6ba598914ec49d7ad5d","claim":"Trevi Therapeutics, Inc. reported quarter ended September 30, 2023 results: net income net loss of $7.7 million.","evidence_excerpt":"For the third quarter of 2023, the Company reported a net loss of $7.7 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017023062031/0000950170-23-062031-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2023"},{"label":"Net income","value":"net loss of $7.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}